Clinical Trial With Broccoli Sprout Extract to Patients With Type 2 Diabetes
Status:
Active, not recruiting
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
Type 2 diabetes (T2D) results from a combination of insufficient insulin secretion from
pancreatic islets and insulin resistance of target cells. The investigators have extensive
pre-clinical data suggesting that BSE through its high content of the isothiocyanate
sulforaphane improves hepatic insulin sensitivity. BSE as a dietary supplement could
therefore benefit both patients with T2D and individuals at risk for the disease.
BSE-containing sulforaphane is suggested to activate Nuclear factor-like 2 (NRF2). The
investigators aim to study the clinical effect of using BSE as a dietary supplement on
glucose tolerance and insulin sensitivity.